Effects of eosinophil granule proteins on human corneal epithelial cell viability and morphology

Investigative Ophthalmology and Visual Science

Volumn 38, Issue 3, 1997, Pages 593-599

  Trocmé, Stefan D ^a,d   Hallberg, Csilla K ^a   Gill, Kuljit S ^a   Gleich, Gerald J ^b   Tyring, Stephen K ^c   Brysk, Miriam M ^c  

^a Eye Research Laboratory   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

eosinophil cationic protein; eosinophil major basic protein; eosinophil peroxidase; eosinophil derived neurotoxin; vernal corneal ulcerations

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; MAJOR BASIC PROTEIN; NEUROTOXIN; PEROXIDASE;

ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA EPITHELIUM; DOSE RESPONSE; EOSINOPHIL; HUMAN; HUMAN CELL; HUMAN TISSUE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING;

BLOOD PROTEINS; CELL SURVIVAL; CELLS, CULTURED; COLORING AGENTS; CORNEA; EOSINOPHIL GRANULE PROTEINS; EOSINOPHIL PEROXIDASE; EOSINOPHIL-DERIVED NEUROTOXIN; EPITHELIAL CELLS; EPITHELIUM; HUMANS; INFLAMMATION MEDIATORS; NEUROTOXINS; PEROXIDASES; RIBONUCLEASES; TETRAZOLIUM SALTS; THIAZOLES;

EID: 0030945247     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Trocme SD, Aldave AJ. The eye and the eosinophil. Surv Ophthalmol. 1994;39:241-252.
2. Trocme SD, Raizman MB, Bartley GB. Medical ther- apy for ocular allergy. Mayo Clin Proc. 1992;67:557-565.
3. Gleich GJ, Frigas E, Loegering DA, et al. Cytotoxic properties of the eosinophil major basic protein. J Immunol. 1979;123:2925-2927.
4. Gleich GJ, Kita H, Adolphson CR. Eosinophils. In: Frank MM, Austen KF, Glaman HN, Unanue ER, eds. Samter's Immunologic Diseases. 5th ed. Boston: Little, Brown; 1995:205-245.
5. Thomas LL, Zheutlin LM, Gleich GJ. Pharmacological control of human basophil histamine release stimu- lated by eosinophil granule major basic protein. Immunology. 1989;66:611-615.
6. Moy JN, Gleich GJ, Thomas LL. Noncytotoxic activation of neutrophils by eosinophil granule major basic protein. Effect on Superoxide anion generation and lysosomal enzyme release. J Immunol. 1990;145:2626-2632.
7. Zheutlin LM, Ackerman SJ, Gleich GJ, Thomas LL. Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. J Immunol. 1984;133:2180-2185.
8. Motojima S, Frigas E, Loegering DA, Gleich GJ. Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am Rev Respir Dis. 1989;139:801-805.
9. Tai PC, Ackerman SJ, Spry CJ, Dunnette S, Olsen EG, Gleich GJ. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet. 1987;1:643-647.
10. Ackerman SJ, Gleich GJ, Loegering DA, Richardson BA, Butterworth AE. Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of Schistosoma mansoni. Am J Trop Med Hyg. 1985;34:735-745.
11. Hamann KJ, Gleich GJ, Checkel JL. In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. J Immunol. 1990;144:3166-3173.
12. Jong EC, Klebanoff SJ. Eosinophil-mediated mammalian tumor cell cytotoxicity: Role of the peroxidase system. J Immunol. 1980;124:1949-1953.
13. Jong EC, Henderson WR, Klebanoff SJ. Bactericidal activity of eosinophil peroxidase. J Immunol. 1980;124:1378-1382.
14. Henderson WR, Chi EY, Klebanoff SJ. Eosinophil peroxidase-induced mast cell secretion. J Exp Med. 1980;152:265-279.
15. Zabucchi G, Menegazzi R, Cramer R, et al. Mutual influence between eosinophil peroxidase (EPO) and neutrophils: Neutrophils reversibly inhibit EPO enzymatic activity and EPO increases neutrophil adhesiveness. Immunology. 1990;69:580-587.
16. Nakajima H, Loegering DA and Gleich GJ. Cytotoxicity of eosinophil granule proteins for tumor cells. FASEB J. 1988;2:A811.
17. Hamann KJ, Barker RL, Checkel JL, McCall JW, Gleich GJ. Eosinophil peroxidase-mediated toxicity to microfilariae of Brugia pahangi and Brugia malayi. Fed Proc. 1987;46:615.
18. Hamann KJ, Barker RL, Loegering DA, Gleich GJ. Comparative toxicity of purified human eosinophil granule proteins for newborn larvae of Trichinella spiralis. J Parasitol. 1987;73:523-529.
19. McLaren DJ, Peterson CG, Venge P. Schistosoma mansoni: Further studies of the interaction between schistosomula and granulocyte-derived cationic proteins in vitro. Parasitology. 1984;88:491-503.
20. Durack DT, Ackerman SJ, Loegering DA, Gleich GJ. Purification of human eosinophil-derived neurotoxin. Proc Natl Acad Sci USA. 1981;78:5165-5169.
21. Fredens K, Dahl R, Venge P. The Gordon phenome- non induced by the eosinophil cationic protein and eosinophil protein X. J Allergy Clin Immunol. 1982;70:361-366.
22. Gullberg U, Widegren B, Arnason U, Egesten A, Olsson I. The cytotoxic eosinophil cationic protein (ECP) has ribonuclease activity. Biochem Biophys Res Commun. 1986;139:1239-1242.
23. Slifman NR, Loegering DA, McKean DJ, Gleich GJ. Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. J Immunol. 1986;137:2913-2917.
24. Filley WV, Kephart GM, Holley KE, Gleich GJ. Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet. 1982;2:11-16.
25. Gleich GJ. The late phase of the immunoglobulin Emediated reaction: A link between anaphylaxis and common allergic disease? J Allergy Clin Immunol. 1982;70:160-169.
26. Venge P, Dahl R, Fredens K, Peterson CG. Epithelial injury by human eosinophils. Am Rev Respir Dis. 1988;138(6 Pt 2):S54-57.
27. Trocme SD, Kephart GM, Allansmith MR, Bourne WM, Gleich GJ. Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis. Am J Ophthalmol. 1989;108:57-63.
28. Udell IJ, Gleich GJ, Allansmith MR, Ackerman SJ, Abelson MB. Eosinophil granule major basic protein and Charcot-Leyden crystal protein in human tears. Am J Ophthalmol. 1981;92:824-828.
29. Saiga T, Shimizu Y. Activated eosinophils in vernal keratoconjunctivitis. Nippon Rinsho-Jap J Clin Med. 1993;51:816-819.
30. Trocme SD, Kephart GM, Bourne WM, Buckley RJ, Gleich GJ. Eosinophil granule major basic protein deposition in corneal ulcers associated with vernal keratoconjunctivitis. Am J Ophthalmol. 1993;115:640-643.
31. Trocme SD, Gleich GJ, Kephart GM, Zieske JD. Eosinophil granule major basic protein inhibition of corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 1994;35:3051-3056.
32. Mack KA, Hallberg CK, Gleich GJ, Trocme SD. Eosinophil cationic protein inhibits corneal epithelial migration in the rat. ARVO Abstracts. Invest Ophthalmol Vis Sci. 1994;35:1943.
33. Pineda AA, Brzica SM Jr., Taswell HF. Continuous-and semicontinuous-flow blood centrifugation systems: Therapeutic applications with plasma-, platelet-, lympha-, and eosinapheresis. Transfusion. 1977;17:407-416.
34. Gleich GJ, Loegering DA, Mann KG, Maldonado JE. Comparitive properties of the Charcot-Leyden crystal protein and the major basic protein from human eosinophils. J Clin Invest. 1976;57:633-640.
35. Ten RM, Pease LR, McKean DJ, Bell MP, Gleich GJ. Molecular cloning of the human eosinophil peroxidase. J Exp Med. 1989;169:1757-1769.
36. Grant RL, Acosta D. Comparative toxicity of tetracaine, proparacaine and cocaine evaluated with primary cultures of rabbit corneal epithelial cells. Exp Eye Res. 1994;58:469-478.
37. Acosta D, Chappell R. Cardiotoxicity of diazepam in cultured heart cells. Toxicology. 1977;8:311-317.
38. Kotnik V, Fleischmann WR Jr. A simple and rapid method to determine hematopoietic growth factor activity. J Immunol Methods. 1990;129:23-30.
39. Tada H, Shiho O, Kuroshima K, Koyama M, Tsukamoto K. An improved colorimetric assay for interleukin 2. J Immunol Methods. 1986;93:157-165.
40. Young JD, Peterson CG, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature. 1986;321:613-616.
41. Abu-Ghazaleh RI, Gleich GJ, Prendergast FG. Interaction of eosinophil granule major basic protein with synthetic lipid bilayers: a mechanism for toxicity. J Membr Biol. 1992;128:153-164.
42. Trocme SD, Hallberg C. Heparin prevents eosinophil granule major basic protein inhibition of corneal epithelial wound healing in the rat. ARVO Abstracts. Invest Ophthalmol Vis Sci. 1993;34:1317.
43. Buttenvorth AE, Wassom DL, Gleich GJ, Loegering DA, David JR. Damage to schistosomula of Schistosoma mansoni induced directly by eosinophil major basic protein. J Immunol. 1979;122:221-229.
44. Marinovich M. The role of actin in the transduction of toxic effect. Pharmacol Res. 1991;24:319-336.
45. Anderson RA. Actin filaments in normal and migrating corneal epithelial cells. Invest Ophthalmol Vis Sci. 1977;16:161-166.
46. Dass BA, Soong HK, Lee B. Effects of proparacaine on actin cytoskeleton of corneal epithelium. J Ocular Pharmacol Ther. 1988;4:187-194.
47. Nicolson GL, Smith JR, Poste G. Effects of local anesthetics on cell morphology and membrane-associated cytoskeletal organization in BALB/3T3 cells. J Cell Biol. 1976;68:395-402.
48. Ayars GH, Altman LC, Gleich GJ, Loegering DA, Baker CB. Eosinophil- and eosinophil granule-mediated pneumocyte injury. J Allergy Clin Immunol. 1985;76:595-604.